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ABSTRACT Mycoplasma genitalium is an important and emerging agent of sexually
transmitted infection in females and males, carrying the potential for postinfection
genital tract sequelae. Past efforts to identify this organism on a routine basis, which
were problematic due to the fastidious nature of the bacterium and its antigenic in-
tricacies, have recently become supplemented by molecular diagnostics. A number
of these assays are available commercially. This minireview describes the format and
performance indices of a number of M. genitalium DNA- and RNA-based ampliﬁca-
tion assays; many of these assays have contributed to an improved clinical and epi-
demiologic understanding of this organism.
KEYWORDS Mycoplasma genitalium, PCR, molecular diagnostics, transcription-
mediated ampliﬁcation
In 1981, the ﬁrst report of recovery and identiﬁcation of Mycoplasma genitalium, thesmallest free-living microorganism capable of reproduction, was published (1). How-
ever, the fastidious nature of this intracellular bacterium signiﬁcantly limits its ability to
be cultivated in an in vitro setting (2). Attempts at serologic diagnosis have been
confounded by antigenic variation of M. genitalium (3) and immunogenic analogs
observed in other Mollicutes, such as Mycoplasma pneumoniae (4). These paradigms are
unfortunate because of the long-standing association of M. genitalium with nongono-
coccal and nonchlamydial urethritis in males (2) and an emerging collection of litera-
ture implicating the organism in cervicitis, pelvic inﬂammatory disease, preterm birth,
and spontaneous abortion (5). Other investigators have reported promotion of HIV
acquisition (6) and shedding (7) by antecedent M. genitalium infection.
Initial efforts to alleviate the gap in laboratory diagnosis of M. genitalium infection
involved molecular assays performed in research settings. Hooton et al. (8) utilized a
radiometric dot hybridization assay to detect M. genitalium DNA from 30 of 203 male
urethral swabs. Jensen et al. (9) targeted the M. genitalium 140-kDa adhesion protein
gene (MgPa) in 150 urogenital specimens that were originally collected for Chlamydia
trachomatis culture. Restriction digestion and hybridization identiﬁed the target in 6.7%
of specimens. MgPa nomenclature will be used in this paper in reference to genetic
derivatives of the adhesion protein gene frequently used in assay development.
In an attempt to highlight M. genitalium diagnostic advancements, a PubMed
primary literature search (U.S. National Library of Medicine and the National Institutes
of Health), conducted on 8 May 2017, selected 417 in-print English language citations
from the years 1991 to 2017 (Fig. 1). Ten additional manuscripts had a status of
electronic publication ahead of print. Nearly 27% of the aforementioned publications
entered the literature between 2006 and 2011, perhaps coinciding with some of the
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ﬁrst commercial attempts at assay development; over 41% have been published since
2012, which may be in line with increasing reports of clinical macrolide treatment
failure and concomitant development of molecular assays to alert clinicians to this
possibility. This brief commentary, with a focus largely on literature published within
the past 2 years, provides an update on M. genitalium molecular diagnostics and
suggests that these assays may soon become commonplace for the clinical microbiol-
ogist.
COMMERCIALLY DEVELOPED DNA AMPLIFICATION ASSAYS
A number of commercially produced M. genitalium DNA ampliﬁcation modalities
have been described. M. genitalium-speciﬁc dual-priming oligonucleotide primers have
been incorporated into a multiplex PCR assay for six sexually transmitted infection (STI)
agents, with subsequent detection of end products via auto-capillary electrophoresis
(Seeplex STD6 ACE; Seegene, Seoul, South Korea). One evaluation (10), performed on
739 urogenital specimens, was limited by utilization of a monoplex PCR (using the same
primer sets) to conﬁrm positive results and by M. genitalium DNA being detected from
only two specimens. Kweon et al. (11) evaluated a PCR microarray capable of detecting
13 agents of genitourinary tract infection (STDetect Chip; LabGenomics, Seongnam,
South Korea) using a combination of prospective vaginal and urine specimens that was
augmented by archived specimens. When compared to direct sequencing of PCR
products generated by primers to the MgPa operon, the assay yielded concordance and
sensitivity values of 99.4% and 98.1%, respectively, in this study set with an 11% M.
genitalium detection rate. The method required independent nucleic acid extraction
and demonstrated 100% concordance with results of the Seeplex STD6 ACE within a
subset of 87 specimens.
Additional attempts to detect M. genitalium DNA have come in the context of assays
FIG 1 Frequency of Mycoplasma genitalium molecular diagnostics publications in English from 1991 to 2017 as determined by the search
parameter “Mycoplasma genitalium” ﬁltered by the possibilities of “molecular diagnostics,” “molecular testing,” “NAAT,” “nucleic acid ampliﬁcation
testing,” “PCR,” “LAMP,” “TMA,” or “transcription-mediated ampliﬁcation.”
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designed for genital Mycoplasmataceae. Takanashi et al. (12) applied PCR target am-
pliﬁcation and Invader-based signal ampliﬁcation (InvaderPlus; LSI Medience Corpora-
tion, Tokyo, Japan) to detection of M. genitalium, Mycoplasma hominis, Ureaplasma
urealyticum, and Ureaplasma parvum from male ﬁrst-void urine samples. Detection
speciﬁcity emanates from triple-stranded hybridization complexes and Cleavase en-
zyme activity. When compared to a research PCR microtiter plate hybridization assay,
a kappa value of 0.961 was attained for InvaderPlus in the context of 15 positive
specimens. Incorporation of internal control nucleic acid revealed endogenous inhibi-
tion within 12 of 171 specimens. Kriesel et al. (13) assessed a research-use-only nested
multiplex PCR assay for detection of M. genitalium, U. urealyticum, and seven other STI
agents (FilmArray STI panel; BioFire Diagnostics, Salt Lake City, UT) with 295 clinical
specimens and used standard-of-care laboratory offerings as reference methods. How-
ever, with respect to M. genitalium, no reference was employed since testing for this
organism was not offered to clinicians at that time. M. genitalium DNA was detected in
3% of specimens (ﬁve urine samples, one genital swab, one rectal swab, one pharyngeal
swab). Kappa values of 0.97 were attained with FilmArray STI panel assessment of
Neisseria gonorrhoeae and C. trachomatis infections when compared to FDA-cleared
Amplicor assays (Roche Molecular Diagnostics).
The LightMix Mycoplasma genitalium kit (TIB Molbiol, Berlin, Germany) is a commer-
cially available real-time PCR assay that requires nucleic acid extraction apart from the
kit. The assay, targeting a 224-bp gap sequence, was applied to the cobas z 480
analyzer (14). In a study of 104 archived urogenital DNA extracts, kit-provided internal
control was ampliﬁed in all instances. When compared to a research M. genitalium PCR
reference standard, sensitivity and speciﬁcity of the LightMix Mycoplasma genitalium kit
were 92.6% and 100%, respectively.
A number of M. genitalium DNA ampliﬁcation assays have received Conformité
Européene in vitro diagnostic (CE) marking. The Bio-Rad Dx CT/NG/MG assay
(Bio-Rad, Marnes-la-Coquette, France) is a multiplex PCR assay that incorporates an
internal control and provides a lysis reagent for manual nucleic acid extraction. The
assay is CE-marked for performance on vaginal, cervical, and urethral swabs as well
as female and male ﬁrst-void urine samples. M. genitalium MgPa ampliﬁcation and
detection occur in manufacturer-provided instrumentation. When compared to
research MgPa PCR results, the Bio-Rad Dx CT/NG/MG assay exhibited 100% sensi-
tivity from 658 female and male urogenital specimens acquired from 453 French STI
clinic patients (15). However, just 11 specimens had detectable M. genitalium DNA
using the evaluated method, one of which (vaginal swab collection) was classiﬁed
as a false-positive result.
The Hyplex STD Mycoplasma test system (Amplex BioSystems, Lich, Germany) is a
CE-marked multiplex PCR for detection of M. genitalium, M. hominis, U. urealyticum, and
U. parvum. A prototype of this assay was reported to have 87% sensitivity and 96%
speciﬁcity for detection of M. genitalium MgPa (16). Khatib et al. (17) utilized this assay
(in concert with commercial RNA methods for C. trachomatis, N. gonorrhoeae, and
Trichomonas vaginalis detection) for assessment of symptomatic males in the United
Kingdom. M. genitalium DNA was detected in 11 of 83 (13.3%) ﬁrst-void urine speci-
mens and was the only agent detected in six of those specimens. All positive ﬁndings
were conﬁrmed by research M. genitalium PCR. A total of 42.2% of specimens in this
report had no detectable nucleic acid speciﬁc to C. trachomatis, N. gonorrhoeae, T.
vaginalis, M. genitalium, or U. urealyticum.
The AmpliSens N. gonorrhoeae/C. trachomatis/M. genitalium/T. vaginalis-Multiprime-
FRT assay (InterLabScience, Moscow, Russia) is a CE-marked real-time PCR assay con-
taining an internal control that requires independent nucleic acid extraction. Ampliﬁ-
cation and detection of M. genitalium gyrB is facilitated by an open-channel platform.
Rumyantseva et al. (18) evaluated this assay using 1,261 frozen specimens originally
collected from Swedish STI clinic attendees in transport medium speciﬁc to a commer-
cial RNA ampliﬁcation system. AmpliSens M. genitalium data were compared to those
of two reference commercial RNA ampliﬁcation assays. Overall AmpliSens sensitivity
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was 81.9%, with a range of 76.5% to 84.8% among vaginal specimens and ﬁrst-void
urine samples from both genders. No false-positive results were derived from the
AmpliSens assessment; 59 patients yielded detectable M. genitalium RNA within this
study.
Le Roy et al. (14) evaluated the CE-marked Mycoplasma genitalium real-time PCR kit
targeting mg219 (Diagenode, Seraing, Belgium) using a cobas z 480 open-channel
system. Performance indices from 104 archival nucleic acid extracts included 100%
speciﬁcity when compared to research M. genitalium PCR results and 87% sensitivity
(seven false-negative results). Kit-provided internal control was ampliﬁed in all cases. A
newer generation assay allows for simultaneous detection of M. genitalium and T.
vaginalis. This S-DiaMGTV kit (Diagenode) was subjected to a 1,569-specimen evalua-
tion from STI clinic and general practice patients in the Netherlands (19). The assay was
facilitated by open-channel ampliﬁcation and detection; DNA extraction apart from the
kit was required. All positiveM. genitalium results, along with 100 negative results, were
veriﬁed by reference laboratory M. genitalium PCR. No M. genitalium testing discrep-
ancies were reported. The study, undertaken to generate point prevalence data and
address empirical treatment guidelines, revealed M. genitalium and T. vaginalis detec-
tion rates of 4.0% and 1.3%, respectively.
Using the same assay, Pereyre et al. (20) reported an M. genitalium detection rate of
3.4% and a T. vaginalis detection rate of 1.7% from 2,652 consecutive female and male
urogenital specimens collected in 16 French university hospitals. Of the 88 patients that
were positive for M. genitalium DNA, 38.6% were coinfected with C. trachomatis, N.
gonorrhoeae, or T. vaginalis. Within a subset of 34 males with detectable M. genitalium
DNA, close to 6% prevalence was noted in a 35- to 44-year-old demographic. A total of
70.9% of patients across both genders with detectable M. genitalium DNA were
asymptomatic.
Fast-track diagnostics (Sliema, Malta) produces a number of CE-marked multiplex
qualitative PCR assays for STI agents that allow for M. genitalium MgPa detection from
ﬁrst-void urine, genital, and rectal collections. The assays include an internal control and
require additional instruments for DNA extraction and target ampliﬁcation/detection.
However, a paucity of peer-reviewed studies exists comparing assay performance to
other molecular diagnostic modalities. Gossé et al. (21) adapted the FTD Urethritis basic
assay to a quantitative PCR format to investigate a test-of-cure paradigm for azithro-
mycin therapy. Using daily ﬁrst-void urine specimens over the course of 14 days, the
authors concluded that ﬂuctuations in bacterial counts hypothetically result in false-
negative tests of cure. Consequently, the authors advocated M. genitalium mutation
analysis at time of organism detection as an optimal means of addressing therapeutic
options.
The CE-marked ResistancePlus MG kit (SpeeDx, Sydney, Australia) utilizes PlexZyme/
PlexPrime technology for real-time quantitative PCR (qPCR) detection of M. genitalium
on an open-channel platform. The multiplex assay includes an internal control and can
identify mutations in 23S rRNA sequences encoding macrolide resistance. An assay
prototype was described by Tabrizi et al. (22) using an Australian cohort of 254 M.
genitalium-infected patients during clinical follow-up. In a collection of 400 urine/
urethral swab, cervical/vaginal swab, and anal swab specimens, the evaluated assay
achieved 99.0% concordance in comparison to a research 16S rRNA gene qPCR refer-
ence. Four noted discrepant specimens each contained a low M. genitalium copy
number. With respect to organism detection by the ResistancePlus MG kit, a retrospec-
tive assessment of 206 urogenital specimens produced a kappa value of 0.98 when
compared to a combined research PCR and S-DiaMGTV reference standard (23). One
ResistancePlus MG result was false-negative (98.9% sensitivity), and internal control
ampliﬁcation failure occurred at a rate of 0.48%. Taken together, this assay may be
positioned to address current and future conundrums of clinical M. genitalium resis-
tance.
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COMMERCIALLY DEVELOPED RNA AMPLIFICATION ASSAYS
Over 10 years have passed since the initial formulation of RNA ampliﬁcation assays
speciﬁc to M. genitalium 16S rRNA using transcription-mediated ampliﬁcation (TMA;
Hologic, San Diego, CA). Hardick et al. (24) determined the sensitivity of research
multitarget PCR (16S rRNA gene, MgPa) and TMA for M. genitalium detection to be
88.8% and 100.0%, respectively, from 286 male urine specimens. M. genitalium preva-
lence exceeded 13% in this U.S. STI clinic demographic. Wroblewski et al. (25) assessed
352 male urine specimens from U.S. STI clinic attendees by research MgPa PCR and
TMA, reporting detection rates of 7.4% and 6.8%, respectively. A preliminary TMA
investigation in females (24) yielded 96.9% sensitivity and 98.4% speciﬁcity from 321
self-collected vaginal swabs in a population with 19.6% M. genitalium prevalence.
Analogous values for multitarget PCR were 93.8% and 99.2%. The other report (25)
noted sensitivity values of M. genitalium TMA (relative to a standard of a patient
yielding a positive research PCR or TMA result) from vaginal and cervical specimens as
being 84% and 60%, respectively. Comparative values for research PCR were 91% and
53%. Prevalence rates derived from these specimen sources ranged from 9% to 14%.
Wroblewski et al. (25) introduced the prospect of alternative specimen sources for
female screening. Sensitivity values of MgPa PCR and TMA assays on female ﬁrst-void
urine samples (relative to a standard of a patient being positive for either test) were
calculated at 65% and 58%, respectively. The authors did not provide information
regarding urine preservation, other than the fact that specimens were archived at
80°C prior to analysis. These data come with the additional caveat that cell wall-
deﬁcient microbes, such as M. genitalium, are likely more susceptible to lytic activities
or components endogenous to urine (25). Data concerning another STI pathogen, T.
vaginalis, may be extrapolated into the potential value of ﬁrst-void urine samples as a
noninvasive screen for M. genitalium in females using TMA. Using a molecular-resolved
algorithm, Nye et al. (26) determined the sensitivity values of commercial T. vaginalis
TMA on 296 ﬁrst-void female urine, endocervical, and vaginal specimens to be 87.5%,
89.8%, and 96.6%, respectively. Analogous values derived from PCR were 76.1%, 80.9%,
and 83.0%. These data further provide evidence for the enhanced analytical sensitivity
of commercial TMA versus conventional DNA ampliﬁcation methods. Potential expla-
nations for this difference (oligonucleotide-based target capture for removal of endog-
enous inhibitors, differences in nucleic acid target quantity), which may further pro-
mote the value of urine screening efforts, have been discussed in a previous review (27).
TMA-based detection of M. genitalium has subsequently been adapted to an
analyte-speciﬁc reagent (ASR) format on automated analyzers. In a study of males from
an STI clinic and community care settings (apart from the STI clinic) in a high-
prevalence U.S. STI community (28), residual contents of 2,750 consecutive ﬁrst-void
urine samples, preserved in Aptima urine specimen transport tubes (Hologic) within 24
h of primary void, were subjected to M. genitalium ASR on TIGRIS automation. The M.
genitalium ASR detection rate (6.84%) nearly equaled that generated by C. trachomatis
TMA (6.87%) and exceeded those of N. gonorrhoeae TMA and laboratory-validated T.
vaginalis TMA. M. genitalium distribution, when delineated by patient age, was similar
to distributions exhibited by N. gonorrhoeae and C. trachomatis.
STI phenotype can be deﬁned as M. genitalium, C. trachomatis, N. gonorrhoeae, and
T. vaginalis distribution within a given health care encounter that yields detection of at
least one STI agent. This measure essentially denotes the probability that a given agent
is the etiology of the STI diagnosed during that encounter. In the aforementioned study
(28), a dichotomy of STI prevalence emerged when comparing STI phenotypes involv-
ing M. genitalium and T. vaginalis (Table 1). Sole detection of M. genitalium was
documented in 36.5% of STI clinic visits that yielded at least one STI; this frequency was
22.0% within community care encounters (P  0.0007). Overall detection of M. geni-
talium STI phenotype occurred in 47.4% of STI clinic visits that generated at least one
STI; that value was 29.7% within community care encounters. In contrast, while 5.3% of
STI clinic visits that yielded at least one STI involved sole detection of T. vaginalis, 18.7%
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of community care visits that generated at least one STI demonstrated sole detection
of T. vaginalis. A total of 7.1% of STI clinic encounters with at least one detectable STI
agent yielded T. vaginalis, while the analogous value in community care was 21.1%.
A community-wide study (with broad demographic and acuity-of-illness coverage)
in the same U.S. high-prevalence STI community assessed M. genitalium ASR using
2,478 residual female specimens submitted for routine laboratory screening of C.
trachomatis, N. gonorrhoeae, and T. vaginalis (29). The M. genitalium detection rate was
11.4% and exceeded those of the other STI agents (P  0.005). Sufﬁcient material
following primary M. genitalium ASR performance allowed for repeat testing of 208 M.
genitalium-positive specimens; 207 (99.5%) yielded a positive result. Furthermore, a
subset of 242 specimens was subjected to M. genitalium TMA with an alternative target.
A 98.8% overall concordance of results was observed, including a 99.5% concordance
rate among 213 specimens that initially yielded a negative M. genitalium ASR result.
Age distribution of females with detectable M. genitalium mirrored those of females
infected with C. trachomatis and N. gonorrhoeae.
M. genitalium detection rates, stratiﬁed by specimen source, ranged from 10.1%
(ﬁrst-void urine) to 13.8% (vaginal swab). As only 138 vaginal specimens were assessed
on the basis of this representative, retrospective collection, the 13.8% vaginal swab
detection rate was not signiﬁcantly increased over that of urine (P  0.23). The cervical
swab detection rate from 1,896 specimens (11.5%) demonstrated no signiﬁcant differ-
ence versus those of ﬁrst-void urine and vaginal swab (P  0.41). These data were
limited by all specimens being collected in routine clinical practice, during which
multiple patient samplings did not occur.
Nonutilization of the M. genitalium ASR would result in signiﬁcant missed opportu-
nities for STI detection. Of the 282 overall M. genitalium detections, M. genitalium was
the sole STI agent detected in 203 (72.0%) of these instances (Table 2). In this
high-prevalence population, one speciﬁc patient demographic demonstrated a greater
proclivity for this organism. When compared to highly prevalent T. vaginalis (9.0%
overall detection rate), M. genitalium detection rates from inpatient obstetric/gyneco-
logic (OB/GYN), suburban family care, urban family care, and emergency room (ER)/
urgent care settings showed little variation (P  0.37) (Table 2). However, the M.
genitalium detection rate from 1,032 outpatient OB/GYN clinic patients (10.3%) was
elevated versus that of T. vaginalis (6.4%; P  0.001). Moreover, relative to the M.
genitalium sole detection paradigm, 80.2% of outpatient OB/GYN clinic patients with
TABLE 1 Sexually-transmitted infection phenotype determined by transcription-mediated ampliﬁcation speciﬁc for Mycoplasma
genitalium, Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis within screened males who were positive for at least
one STIa
STI phenotypeb,c No. (%) of patients delineated by healthcare setting
M. genitalium C. trachomatis N. gonorrhoeae T. vaginalis STI clinic Community care P value
    97d (36.5)e 46 (22.0) 0.0007
    17 (6.4) 10 (4.8) 0.45
    9 (3.4) 2 (1.0) 0.08
    69 (25.9) 67 (32.1) 0.14
    10 (3.8) 13 (6.2) 0.22
    44 (16.5) 26 (12.4) 0.21
    14 (5.3) 39 (18.7) 0.0002
Any M. genitalium detection 126 (47.4) 62 (29.7) 0.0002
Any C. trachomatis detection 97 (36.5) 92 (44.0) 0.10
Any N. gonorrhoeae detection 68 (25.6) 43 (20.6) 0.20
Any T. vaginalis detection 19 (7.1) 44 (21.1) 0.0002
aAdapted from reference 28 with permission from Elsevier.
b, positive transcription-mediated ampliﬁcation screen; , negative transcription-mediated ampliﬁcation screen.
cPhenotypes that were observed in 1.5% of patients at both the STI clinic and community care are not included in this table. No signiﬁcant difference was noted
within each of these comparisons.
dThis value indicates the number of phenotypes.
eThis value indicates the percentage of phenotypes per clinic distribution.
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detectable M. genitalium did not exhibit STI codetection (Table 2). This rate was
elevated over those for ER/urgent care patients (68.2% M. genitalium sole detection)
and urban family care patients (63.4% M. genitalium sole detection; both P  0.04).
A retrospective, seven-center U.S. study (30) conﬁrmed and extended several of the
ﬁndings from the previous two studies. M. genitalium and C. trachomatis prevalence
rates (17.2% and 17.8%, respectively) were equally high among males. The female M.
genitalium ASR detection rate (16.3%) was signiﬁcantly higher than those of C. tracho-
matis and N. gonorrhoeae but less than that of T. vaginalis. Signiﬁcant associations were
made between M. genitalium detection and non-Hispanic ethnicity, African American
race, younger age, and female symptomatic status. Moreover, a high frequency of
single-agent infection was demonstrated.
Tabrizi et al. (31) evaluated an M. genitalium TMA assay on the automated Panther
platform (Hologic) in comparison to a composite molecular standard comprised of an
alternative target TMA assay, 16S rRNA gene PCR, and MgPa PCR. Sensitivity and
speciﬁcity values for the CE-marked assay were 100% and 93.6%, respectively, from
1,080 urine specimens collected from a diverse clinical population with nearly 9% M.
genitalium prevalence. Sensitivity values for the two PCR assays ranged from 89.1% to
91.3%. These data extend earlier ﬁndings (18, 24, 26) regarding the improved potential
of STI agent detection using TMA modalities.
OUTLOOK
The ﬁeld of molecular diagnostics, particularly in the last 8 to 10 years, has strived
to fulﬁll an unmet clinical need with respect to this fastidious organism. Differences in
M. genitalium prevalence exist throughout the world (references 10, 13, 15, and 18 to
20 discuss low prevalence; references 17, 24, 25, and 28 to 33 discuss high prevalence),
which may inﬂuence local routine screening decisions. The possibility does exist that
the lower sensitivity of DNA ampliﬁcation testing may result in an underestimation of
prevalence. However, concern for macrolide-resistant strains of M. genitalium may
supersede some of these lower-prevalence data in providing impetus for clinical
screening. Less-invasive means of specimen collection, such as ﬁrst-void urine or
self-collected vaginal swab options, may promote a higher screening frequency, par-
ticularly in scenarios that do not require a physical examination. Furthermore, Dize et
al. (32) reported that M. genitalium ASR performed on self-collected penile-meatal
swabs (investigated in a U.S. STI clinic with 14% M. genitalium prevalence) yielded
performance indices equivalent to those derived from clinician-collected urethral
swabs.
As clinical microbiologists encounter the increased availability of M. genitalium
molecular diagnostics, including those ultimately receiving FDA clearance, additional
studies will be necessary to ascertain the optimal specimen source in terms of perfor-
mance characteristics and patient accessibility. Moreover, a recent report suggests that
inclusion of multiple analytes and specimen source collections signiﬁcantly increases
detection of STI carrier status (33). Further investigations may be necessary to indicate
TABLE 2 Female Mycoplasma genitalium and Trichomonas vaginalis transcription-mediated ampliﬁcation detection frequencies delineated
by health care settinga
Health care setting No.
Comparative detection frequency (%)
P value
Instances (%) of sole
Mycoplasma genitalium
detectionbMycoplasma genitalium Trichomonas vaginalis
Outpatient OB/GYN 1,032 106 (10.3) 66 (6.4) 0.001 85 (80.2)
Inpatient OB/GYN 46 7 (15.2) 5 (10.9) 0.54 5 (71.4)
Suburban family care 261 18 (6.9) 14 (5.4) 0.47 12 (66.7)
Urban family care 384 41 (10.7) 39 (10.2) 0.81 26 (63.4)c
ER/urgent care 755 110 (14.6) 98 (13.0) 0.37 75 (68.2)d
aAdapted from reference 29.
bThis indicates M. genitalium detections not involving codetection with another STI agent.
cP  0.03 versus instances of sole M. genitalium detection from outpatient OB/GYN.
dP  0.04 versus instances of sole M. genitalium detection from outpatient OB/GYN.
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targeted demographics (20, 28–30) should a fully comprehensive screening approach
not be advocated in a given locale. Consideration of M. genitalium molecular diagnos-
tics within an STI screening algorithm may ultimately realize public health beneﬁts and
improved clinical management.
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